[Diagnosis and management of EBV-positive lymphoproliferative disorders].
Rinsho Ketsueki
; 64(8): 764-771, 2023.
Article
in Ja
| MEDLINE
| ID: mdl-37673629
ABSTRACT
Epstein-Barr virus (EBV) has the ability to immortalize not only B cells but also T and natural killer (NK) cells. The virus may also contribute to the onset of EBV-positive lymphoproliferative disorders (EBV-LPDs) by inducing the introduction of gene mutations. It is known that B cell EBV-LPDs (B-EBV-LPDs) develop with preexisting immunodeficiency, but the onset mechanism of T cell and NK cell EBV-LPDs (T-EBV-LPDs and NK-EBV-LPDs), also known as chronic active EBV disease and associated diseases, is unclear. The diagnosis of both EBV-LPDs requires the quantitative examination of EBV-DNA in the peripheral blood. Eliminating the cause of immunodeficiency or administering rituximab is effective in treating B-EBV-LPDs, but some B-EBV-LPDs and T-EBV-LPDs/NK-EBV-LPDs are resistant to pharmacotherapy. Therefore, further research is needed to explicate the pathophysiology of EBV-LPDs and develop a drug for its treatment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epstein-Barr Virus Infections
/
Lymphoproliferative Disorders
Type of study:
Diagnostic_studies
/
Etiology_studies
Limits:
Humans
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2023
Type:
Article